智通财经APP获悉，2月27日，阿斯利康 (AZN.US) 宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂 (SERD)camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期 ...

经济观察网讯 阿斯利康（AstraZeneca）公司今日（2月27日）宣布，3期临床试验SERENA-6的中期分析显示， 其在研口服选择性雌激素受体降解剂（SERD）camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期（PFS）上显示出统计学显著且具有临床意义的改善。

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

Find insight on AstraZeneca, Fresenius, ConvaTec, and more in the latest Market Talks covering the Health Care sector.

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

AstraZeneca reports positive interim results for camizestrant in Phase 3 SERENA-6 trial, showing PFS benefit in ER-positive ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...